Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.47 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL326764 | 0.88 | CA1 (0.71) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL165878 | 0.86 | POLB (0.76) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL31049616 | 0.86 | CA1 (0.68) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL163935 | 0.86 | CA1 (0.68) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL28501879 | 0.86 | CA1 (0.68) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL7865590 | 0.86 | CA1 (0.72) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL114885 | 0.85 | CA1 (0.67) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL327146 | 0.85 | CA1 (0.64) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL30949366 | 0.84 | POLB (0.74) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL11485622 | 0.84 | CA1 (0.67) | CA1CA2POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424870-B1 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2590969-A2 | THERAPEUTIC AGENTS 976 | AstraZeneca AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| EP-2424870-A1 | THERAPEUTIC AGENTS 713 | AstraZeneca AB (SE) | 2012-03-07 | — | — | EP | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| WO-2012004588-A2 | THERAPEUTIC AGENTS 976 | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2010125390-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | MC1R, MC2R, MC3R | CA1 2214/4885CA2 2731/4885POLB 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.